Jordi Xiol
Directeur/Bestuurslid bij NorthSea Therapeutics BV
Oorsprong van het eerstegraads netwerk van Jordi Xiol
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
University of Barcelona
30
| College/University | Other Consumer Services | 30 |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona.
20
| Private Company | Investment Managers | 20 |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.
13
| Holding Company | Biotechnology | 13 |
SpliceBio SL
 SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation.
8
| Holding Company | Biotechnology | 8 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Jordi Xiol via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder Private Equity Investor Private Equity Investor | |
| Escuela Superior de Administración y Dirección de Empresas | College/University | Corporate Officer/Principal Graduate Degree Graduate Degree | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Founder Director/Board Member | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer | |
| Instituto de Estudios Superiores de la Empresa | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
Medlumics SL
 Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
STAT-Dx Life SL
 STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ARCUS BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Staten Biotechnology BV
 Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| Universitat Pompeu Fabra | College/University | Graduate Degree Graduate Degree | |
| Polytechnic University of Catalonia | College/University | Undergraduate Degree Graduate Degree | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| HOLALUZ-CLIDOM, S.A. | Electric Utilities | Chief Executive Officer Corporate Officer/Principal | |
Aelix Therapeutics SL
 Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
| Universitat Autònoma de Barcelona | College/University | Masters Business Admin Undergraduate Degree | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree | |
Vivet Therapeutics SAS
 Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Founder Director/Board Member | |
Caixa Capital Risc SGEIC SA
 Caixa Capital Risc SGEIC SA Investment ManagersFinance Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital subsidiary of Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid. | Investment Managers | Private Equity Analyst Private Equity Investor | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director of Finance/CFO Founder | |
Ona Therapeutics SL
 Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Founder Director/Board Member | |
| University of Deusto | College/University | Masters Business Admin Masters Business Admin | |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director/Board Member Director/Board Member | |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Chairman Director/Board Member | |
Círculo de Economía
 Círculo de Economía Miscellaneous Commercial ServicesCommercial Services Círculo de Economía is a private company based in Barcelona, Spain that was founded in 1958. The Spanish company's main focus is not explicitly stated in the metadata, but according to the provided 'description', it appears to be involved in award ceremonies and hosting sessions related to economics and politics. The text also mentions a European construction award being given to the mayor of a city, as well as discussions on geopolitical and economic topics. | Miscellaneous Commercial Services | Director/Board Member President | |
| TIGENIX NV | Medical Specialties | Director/Board Member Director of Finance/CFO | |
| CAIXABANK, S.A. | Regional Banks | Director/Board Member Director/Board Member | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Chairman Director of Finance/CFO | |
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Universidad Autónoma de Madrid | College/University | Doctorate Degree Undergraduate Degree | |
| University of Navarra | College/University | Masters Business Admin Undergraduate Degree | |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Perelman School of Medicine | College/University | Doctorate Degree Corporate Officer/Principal | |
| ASCENDIS PHARMA A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
| The University of Colorado | College/University | Corporate Officer/Principal Undergraduate Degree | |
Fira Internacional de Barcelona
 Fira Internacional de Barcelona Miscellaneous Commercial ServicesCommercial Services Fira Internacional de Barcelona organizes trade shows and fairs, as well as corporate and socio-cultural events. It offers catering, logistics, transportation, accommodations, registration services for participants and guests. The company was founded in 1932, and is headquartered in Barcelona, Spain. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Prexton Therapeutics SA
 Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder | |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Chairman Founder | |
| PFIZER, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| AEROVATE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Pennsylvania | College/University | Undergraduate Degree Undergraduate Degree |
Statistieken
Internationaal
| Spanje | 23 |
| Verenigde Staten | 13 |
| Nederland | 5 |
| Denemarken | 5 |
| Zwitserland | 3 |
Sectoraal
| Health Technology | 32 |
| Consumer Services | 13 |
| Finance | 5 |
| Commercial Services | 3 |
| Utilities | 2 |
Operationeel
| Director/Board Member | 379 |
| Corporate Officer/Principal | 98 |
| Independent Dir/Board Member | 67 |
| Chairman | 48 |
| Undergraduate Degree | 47 |
Sterkste connecties
| Insiders | |
|---|---|
| Somu Subramaniam | 48 |
| Ed Mathers Mathers | 47 |
| Cristina Garmendia Mendizábal | 38 |
| Hugo Slootweg | 34 |
| Maha Katabi | 28 |
| Peter Andersen | 26 |
| Hilde Hermansen Steineger | 24 |
| Søren Møller | 21 |
| Reig Carlos Enseñat | 21 |
| Pamela Klein | 19 |
| Pedro Fontana García | 18 |
| Joël Jean-Mairet | 17 |
| Richard Gaster | 17 |
| Karen Wagner | 17 |
| Antoni Ribas | 15 |
- Beurs
- Insiders
- Jordi Xiol
- Bedrijfsconnecties
